Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line

被引:54
|
作者
Tong, Shi-Wen [1 ]
Yang, Yi-Xuan [1 ]
Hu, Huai-Dong [1 ]
An, Xuan [1 ]
Ye, Feng [1 ]
Hu, Peng [1 ]
Ren, Hong [1 ]
Li, Sang-Lin [1 ]
Zhang, Da-Zhi [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 2, Minist Educ China, Key Lab Mol Biol Infect Dis, Chongqing 400016, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
MULTI-DRUG RESISTANCE; HEPATOCELLULAR CARCINOMA; iTRAQ; MASS SPECTROMETRY; MULTIDRUG-RESISTANCE; GROWTH-FACTOR; COLORECTAL-CANCER; EXPRESSION; PROTEIN; IDENTIFICATION; DEHYDROGENASE; METASTASIS; ANNEXIN-A3; INCREASES;
D O I
10.1002/jcb.24036
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multi-drug resistance (MDR) is a major obstacle towards a successful treatment of hepatocellular carcinoma (HCC). The mechanisms of MDR are intricate and have not been fully understood. Therefore, we employed a cell-line model consisting of the 5-fluorouracil (5-FU) resistant BEL7402/5-FU cell line and its parental BEL7402 cell line. Using relative and absolute quantification (iTRAQ)-coupled 2D LC-MS/MS, a successfully exploited high-throughput proteomic technology, in total, 660 unique proteins were identified and 52 proteins showed to be differentially expressed in BEL7402/5-FU compared with BEL7402. Several differentially expressed proteins were further validated by Western blot and real-time quantitative RT-PCR analysis. Furthermore, the association of MDR with ANXA3, one of the highly expressed proteins in BEL7402/5-FU, was verified. Our study represents the first successful application of iTRAQ technology for MDR mechanisms analysis in HCC. Many of the differentially expressed proteins identified had not been linked to MDR in HCC before, which provide valuable information for further understanding of MDR. J. Cell. Biochem. 113: 16711680, 2012. (C) 2011 Wiley Periodicals, Inc.
引用
收藏
页码:1671 / 1680
页数:10
相关论文
共 50 条
  • [21] Activation of MAP kinases by 5-fluorouracil in a 5-fluorouracil-resistant variant human cell line derived from a KT breast cancer cell line
    Wu, YP
    Hiwasa, T
    Isogai, E
    Sonoda, T
    Kita, K
    Chen, Z
    Sugaya, S
    Yamamori, H
    Tanzawa, H
    Suzuki, N
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1998, 13 (06) : 1241 - 1245
  • [22] The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma
    Feng, Xiaodong
    Luo, Qingqiong
    Zhang, Han
    Wang, Han
    Chen, Wantao
    Meng, Guangxun
    Chen, Fuxiang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36
  • [23] Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-α combination chemotherapy
    Moriyama, M
    Hoshida, Y
    Kato, N
    Otsuka, M
    Yoshida, H
    Kawabe, T
    Omata, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 25 (05) : 1279 - 1287
  • [24] Cell Cycle Dysregulation Is Associated With 5-Fluorouracil Resistance in Gastric Cancer Cells
    Kim, Da Som
    Min, Kyoungmi
    Lee, Suk Kyeong
    ANTICANCER RESEARCH, 2020, 40 (06) : 3247 - 3254
  • [25] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer
    Yuan, Jianhui
    Lv, Hui
    Peng, Bo
    Wang, Chengkun
    Yu, Yanhui
    He, Zhimin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (06) : 1103 - 1110
  • [26] Novel Biochemical Pathways for 5-Fluorouracil in Managing Experimental Hepatocellular Carcinoma in Rats
    Abdel-Hamid, Nabil M.
    Morsy, Mohamed A.
    JOURNAL OF MEMBRANE BIOLOGY, 2010, 234 (01) : 29 - 34
  • [27] Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound
    Hu, Zheng
    Lv, Guixiang
    Li, Yongning
    Li, Enze
    Li, Haixia
    Zhou, Qi
    Yang, Bin
    Cao, Wenwu
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
  • [28] Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma
    He, Xiaodong
    Li, Jingjing
    Guo, Weidong
    Liu, Wei
    Yu, Jia
    Song, Wei
    Dong, Lei
    Wang, Fang
    Yu, Shuangni
    Zheng, Yi
    Chen, Songsen
    Kong, Yan
    Liu, Changzheng
    ONCOTARGET, 2015, 6 (04) : 2302 - 2314
  • [29] Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway
    Cao, Liang-qi
    Wang, Xiao-li
    Wang, Qian
    Xue, Ping
    Jiao, Xing-yuan
    Peng, He-ping
    Lu, Hai-wu
    Zheng, Qiang
    Chen, Xi-lin
    Huang, Xiao-hui
    Fu, Xin-hui
    Chen, Jing-song
    ACTA PHARMACOLOGICA SINICA, 2009, 30 (09) : 1316 - 1322
  • [30] The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth
    Hu, Xueli
    Ding, Jie
    Wang, Ge
    Zhang, Xianming
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (03)